NewLink Genetics Corporation (NASDAQ:NLNK) was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued on Wednesday.

A number of other research firms have also recently commented on NLNK. Robert W. Baird reissued an “outperform” rating and set a $25.00 target price on shares of NewLink Genetics Corporation in a research report on Monday, June 5th. Zacks Investment Research cut shares of NewLink Genetics Corporation from a “hold” rating to a “sell” rating in a research report on Wednesday, July 12th. Jefferies Group LLC reissued a “hold” rating and set a $7.00 target price on shares of NewLink Genetics Corporation in a research report on Friday, July 14th. Cantor Fitzgerald set a $26.00 target price on shares of NewLink Genetics Corporation and gave the stock a “buy” rating in a research report on Friday, July 28th. Finally, Stifel Nicolaus boosted their target price on shares of NewLink Genetics Corporation from $14.00 to $29.00 and gave the stock a “buy” rating in a research report on Monday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $24.17.

Shares of NewLink Genetics Corporation (NLNK) opened at 13.19 on Wednesday. The firm has a 50 day moving average of $8.35 and a 200-day moving average of $12.85. NewLink Genetics Corporation has a 12 month low of $5.90 and a 12 month high of $25.17. The stock’s market capitalization is $388.06 million.

NewLink Genetics Corporation (NASDAQ:NLNK) last posted its earnings results on Friday, July 28th. The biotechnology company reported ($0.57) EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.21. NewLink Genetics Corporation had a negative net margin of 161.94% and a negative return on equity of 55.03%. The business had revenue of $10.37 million for the quarter, compared to analysts’ expectations of $2.65 million. Analysts forecast that NewLink Genetics Corporation will post ($2.82) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “NewLink Genetics Corporation (NLNK) Rating Lowered to Sell at ValuEngine” was first published by Daily Political and is owned by of Daily Political. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/09/15/newlink-genetics-corporation-nlnk-rating-lowered-to-sell-at-valuengine.html.

Several large investors have recently modified their holdings of the stock. The Manufacturers Life Insurance Company increased its stake in shares of NewLink Genetics Corporation by 3.0% in the second quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock worth $140,000 after buying an additional 556 shares during the last quarter. State Street Corp increased its stake in shares of NewLink Genetics Corporation by 1.2% in the second quarter. State Street Corp now owns 391,464 shares of the biotechnology company’s stock worth $2,875,000 after buying an additional 4,630 shares during the last quarter. Tudor Investment Corp ET AL bought a new stake in shares of NewLink Genetics Corporation in the second quarter worth $286,000. PDT Partners LLC increased its stake in shares of NewLink Genetics Corporation by 160.2% in the second quarter. PDT Partners LLC now owns 115,795 shares of the biotechnology company’s stock worth $851,000 after buying an additional 71,295 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in shares of NewLink Genetics Corporation by 40.2% in the second quarter. Dimensional Fund Advisors LP now owns 120,767 shares of the biotechnology company’s stock worth $888,000 after buying an additional 34,624 shares during the last quarter. Institutional investors and hedge funds own 54.78% of the company’s stock.

About NewLink Genetics Corporation

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Analyst Recommendations for NewLink Genetics Corporation (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.